Bristol Myers Squibb (Celgene) Deal History & Licensing Activity

About Bristol Myers Squibb (Celgene) Licensing & Deal Activity

Bristol Myers Squibb (Celgene) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 14 deals over the past three years, Bristol Myers Squibb (Celgene) ranks among the most acquisitive companies tracked by Ambrosia Ventures.

Key therapeutic areas of focus for Bristol Myers Squibb (Celgene) include Codev Deals (9 deals and trials), Option Deals (5 deals and trials), Hematological Malignancies (5 deals and trials), and Mega Deals (4 deals and trials). In terms of modality, Bristol Myers Squibb (Celgene) has shown particular interest in other, bispecific antibodies, small molecules.

Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Bristol Myers Squibb (Celgene) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Bristol Myers Squibb (Celgene)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.